Comprehensive Profiling Analysis of CD209 in Malignancies Reveals the Therapeutic Implication for Tumor Patients Infected With SARS-CoV-2
Coronavirus disease 2019 (COVID-19), which is known to be caused by the virus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is characterized by pneumonia, cytokine storms, and lymphopenia. Patients with malignant tumors may be particularly vulnerable to SARS-CoV-2 infection and possi...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2022.883234/full |
| _version_ | 1828319345145544704 |
|---|---|
| author | Jinyuan Li Jinyuan Li Shuzhao Chen Shuzhao Chen Yang Li Yang Li Ziang Zhu Ziang Zhu Hanying Huang Hanying Huang Weida Wang Weida Wang Yao Yang Yang Liang Yang Liang Lingling Shu Lingling Shu Lingling Shu |
| author_facet | Jinyuan Li Jinyuan Li Shuzhao Chen Shuzhao Chen Yang Li Yang Li Ziang Zhu Ziang Zhu Hanying Huang Hanying Huang Weida Wang Weida Wang Yao Yang Yang Liang Yang Liang Lingling Shu Lingling Shu Lingling Shu |
| author_sort | Jinyuan Li |
| collection | DOAJ |
| description | Coronavirus disease 2019 (COVID-19), which is known to be caused by the virus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is characterized by pneumonia, cytokine storms, and lymphopenia. Patients with malignant tumors may be particularly vulnerable to SARS-CoV-2 infection and possibly more susceptible to severe complications due to immunosuppression. Recent studies have found that CD209 (DC-SIGN) might be a potential binding receptor for SARS-CoV-2 in addition to the well-known receptor ACE2. However, pan-cancer studies of CD209 remain unclear. In this study, we first comprehensively investigated the expression profiles of CD209 in malignancies in both pan-carcinomas and healthy tissues based on bioinformatic techniques. The CD209 expression declined dramatically in various cancer types infected by SARS-CoV-2. Remarkably, CD209 was linked with diverse immune checkpoint genes and infiltrating immune cells. These findings indicate that the elevation of CD209 among specific cancer patients may delineate a mechanism accounting for a higher vulnerability to infection by SARS-CoV-2, as well as giving rise to cytokine storms. Taken together, CD209 plays critical roles in both immunology and metabolism in various cancer types. Pharmacological inhibition of CD209 antigen (D-mannose), together with other anti-SARS-CoV-2 strategies, might provide beneficial therapeutic effects in specific cancer patients. |
| first_indexed | 2024-04-13T17:55:02Z |
| format | Article |
| id | doaj.art-473141f84c994be0ac3a77ff4897f450 |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-04-13T17:55:02Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-473141f84c994be0ac3a77ff4897f4502022-12-22T02:36:33ZengFrontiers Media S.A.Frontiers in Genetics1664-80212022-06-011310.3389/fgene.2022.883234883234Comprehensive Profiling Analysis of CD209 in Malignancies Reveals the Therapeutic Implication for Tumor Patients Infected With SARS-CoV-2Jinyuan Li0Jinyuan Li1Shuzhao Chen2Shuzhao Chen3Yang Li4Yang Li5Ziang Zhu6Ziang Zhu7Hanying Huang8Hanying Huang9Weida Wang10Weida Wang11Yao Yang12Yang Liang13Yang Liang14Lingling Shu15Lingling Shu16Lingling Shu17State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaInstitute of Pharmaceutics, School of Pharmaceutical Sciences, Sun Yat-sen University, Shenzhen, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, SAR, ChinaCoronavirus disease 2019 (COVID-19), which is known to be caused by the virus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is characterized by pneumonia, cytokine storms, and lymphopenia. Patients with malignant tumors may be particularly vulnerable to SARS-CoV-2 infection and possibly more susceptible to severe complications due to immunosuppression. Recent studies have found that CD209 (DC-SIGN) might be a potential binding receptor for SARS-CoV-2 in addition to the well-known receptor ACE2. However, pan-cancer studies of CD209 remain unclear. In this study, we first comprehensively investigated the expression profiles of CD209 in malignancies in both pan-carcinomas and healthy tissues based on bioinformatic techniques. The CD209 expression declined dramatically in various cancer types infected by SARS-CoV-2. Remarkably, CD209 was linked with diverse immune checkpoint genes and infiltrating immune cells. These findings indicate that the elevation of CD209 among specific cancer patients may delineate a mechanism accounting for a higher vulnerability to infection by SARS-CoV-2, as well as giving rise to cytokine storms. Taken together, CD209 plays critical roles in both immunology and metabolism in various cancer types. Pharmacological inhibition of CD209 antigen (D-mannose), together with other anti-SARS-CoV-2 strategies, might provide beneficial therapeutic effects in specific cancer patients.https://www.frontiersin.org/articles/10.3389/fgene.2022.883234/fullCD209malignanciesimmune infiltrationSARS-CoV-2bioinformatics |
| spellingShingle | Jinyuan Li Jinyuan Li Shuzhao Chen Shuzhao Chen Yang Li Yang Li Ziang Zhu Ziang Zhu Hanying Huang Hanying Huang Weida Wang Weida Wang Yao Yang Yang Liang Yang Liang Lingling Shu Lingling Shu Lingling Shu Comprehensive Profiling Analysis of CD209 in Malignancies Reveals the Therapeutic Implication for Tumor Patients Infected With SARS-CoV-2 Frontiers in Genetics CD209 malignancies immune infiltration SARS-CoV-2 bioinformatics |
| title | Comprehensive Profiling Analysis of CD209 in Malignancies Reveals the Therapeutic Implication for Tumor Patients Infected With SARS-CoV-2 |
| title_full | Comprehensive Profiling Analysis of CD209 in Malignancies Reveals the Therapeutic Implication for Tumor Patients Infected With SARS-CoV-2 |
| title_fullStr | Comprehensive Profiling Analysis of CD209 in Malignancies Reveals the Therapeutic Implication for Tumor Patients Infected With SARS-CoV-2 |
| title_full_unstemmed | Comprehensive Profiling Analysis of CD209 in Malignancies Reveals the Therapeutic Implication for Tumor Patients Infected With SARS-CoV-2 |
| title_short | Comprehensive Profiling Analysis of CD209 in Malignancies Reveals the Therapeutic Implication for Tumor Patients Infected With SARS-CoV-2 |
| title_sort | comprehensive profiling analysis of cd209 in malignancies reveals the therapeutic implication for tumor patients infected with sars cov 2 |
| topic | CD209 malignancies immune infiltration SARS-CoV-2 bioinformatics |
| url | https://www.frontiersin.org/articles/10.3389/fgene.2022.883234/full |
| work_keys_str_mv | AT jinyuanli comprehensiveprofilinganalysisofcd209inmalignanciesrevealsthetherapeuticimplicationfortumorpatientsinfectedwithsarscov2 AT jinyuanli comprehensiveprofilinganalysisofcd209inmalignanciesrevealsthetherapeuticimplicationfortumorpatientsinfectedwithsarscov2 AT shuzhaochen comprehensiveprofilinganalysisofcd209inmalignanciesrevealsthetherapeuticimplicationfortumorpatientsinfectedwithsarscov2 AT shuzhaochen comprehensiveprofilinganalysisofcd209inmalignanciesrevealsthetherapeuticimplicationfortumorpatientsinfectedwithsarscov2 AT yangli comprehensiveprofilinganalysisofcd209inmalignanciesrevealsthetherapeuticimplicationfortumorpatientsinfectedwithsarscov2 AT yangli comprehensiveprofilinganalysisofcd209inmalignanciesrevealsthetherapeuticimplicationfortumorpatientsinfectedwithsarscov2 AT ziangzhu comprehensiveprofilinganalysisofcd209inmalignanciesrevealsthetherapeuticimplicationfortumorpatientsinfectedwithsarscov2 AT ziangzhu comprehensiveprofilinganalysisofcd209inmalignanciesrevealsthetherapeuticimplicationfortumorpatientsinfectedwithsarscov2 AT hanyinghuang comprehensiveprofilinganalysisofcd209inmalignanciesrevealsthetherapeuticimplicationfortumorpatientsinfectedwithsarscov2 AT hanyinghuang comprehensiveprofilinganalysisofcd209inmalignanciesrevealsthetherapeuticimplicationfortumorpatientsinfectedwithsarscov2 AT weidawang comprehensiveprofilinganalysisofcd209inmalignanciesrevealsthetherapeuticimplicationfortumorpatientsinfectedwithsarscov2 AT weidawang comprehensiveprofilinganalysisofcd209inmalignanciesrevealsthetherapeuticimplicationfortumorpatientsinfectedwithsarscov2 AT yaoyang comprehensiveprofilinganalysisofcd209inmalignanciesrevealsthetherapeuticimplicationfortumorpatientsinfectedwithsarscov2 AT yangliang comprehensiveprofilinganalysisofcd209inmalignanciesrevealsthetherapeuticimplicationfortumorpatientsinfectedwithsarscov2 AT yangliang comprehensiveprofilinganalysisofcd209inmalignanciesrevealsthetherapeuticimplicationfortumorpatientsinfectedwithsarscov2 AT linglingshu comprehensiveprofilinganalysisofcd209inmalignanciesrevealsthetherapeuticimplicationfortumorpatientsinfectedwithsarscov2 AT linglingshu comprehensiveprofilinganalysisofcd209inmalignanciesrevealsthetherapeuticimplicationfortumorpatientsinfectedwithsarscov2 AT linglingshu comprehensiveprofilinganalysisofcd209inmalignanciesrevealsthetherapeuticimplicationfortumorpatientsinfectedwithsarscov2 |